PLEKHA4: A Potential Drug Target and Biomarker for Domain-Containing Family A Members

Target Name: PLEKHA4

NCBI ID: G57664

PLEKHA4

Other Name(s): PH domain-containing family A member 4 | PKHA4_HUMAN | Phosphoinositol 3-phosphate-binding PH domain protein 1 | Phosphoinositol 3-phosphate binding protein-1 | PEPP1 | pleckstrin homology domain containing A4 | PEPP-1 | phosphoinositol 3-phosphate-binding PH domain protein 1 | PLEKHA4 variant 1 | Pleckstrin homology domain-containing family A member 4 | pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 | Pleckstrin homology domain-containing family A member 4 (isoform 1) | Pleckstrin homology domain containing A4, transcript variant 1 | Phosphoinositol 3-phosphate-binding protein 1

PLEKHA4: A Potential Drug Target and Biomarker for Domain-Containing Family A Members

Abstract:

Domain-containing family A (DCA) members are a diverse superfamily of proteins that have been implicated in various cellular processes. PLEKHA4, a member of the PH domain-containing family A, has been identified as a potential drug target and biomarker. This article will summarize the structure and function of PLEKHA4, its potential drug-targeting properties, and its potential as a biomarker for various diseases.

Introduction:

The protein encoded by the PLEKHA4 gene is a member of the PH domain-containing family A (DCA), which is characterized by the presence of a PH domain and multiple well- conserved non-coding regions. PLEKHA4 is a 21-kDa protein that has been shown to play a role in various cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization.

Potential Drug Target:

PLEKHA4 has been identified as a potential drug target due to its unique structure and function. The PH domain is known for its ability to interact with various molecules, including tyrosines and adenylates. This interaction has led to the prediction that PLEKHA4 could be a drug target for mutations in the PH domain that result in abnormal cellular processes. Additionally, the DCA family is known to be involved in various cellular processes, including cell signaling and cell adhesion. Therefore, targeting PLEKHA4 with drugs that modulate its cellular functions could potentially lead to therapeutic benefits for various diseases.

Biomarker Potential:

PLEKHA4 has also been identified as a potential biomarker for various diseases. The DCA family has been shown to be involved in various cellular processes, including cell signaling and cancer progression. Therefore, targeting PLEKHA4 with drugs that modulate its cellular functions could potentially lead to therapeutic benefits for various diseases, including cancer.

Structure and Function:

The PLEKHA4 protein is a 21-kDa protein that contains 195 amino acid residues. It has a unique structure that includes a catalytic PH domain, a cytoplasmic region, and a transmembrane region. The PH domain is the most conserved region of the PLEKHA4 protein and is known for its ability to interact with various molecules, including tyrosines and adenylates.

The PLEKHA4 protein functions as a negative regulator of the MAPK/ERK signaling pathway. This pathway is involved in various cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization. PLEKHA4 has been shown to interact with the MAPK/ERK signaling pathway and has been predicted to play a role in regulating this pathway.

In addition to its role in the MAPK/ERK signaling pathway, PLEKHA4 has also been shown to play a role in cell adhesion and cytoskeletal organization. PLEKHA4 has been shown to interact with the cytoskeleton and has been predicted to play a role in regulating cytoskeletal organization.

Mutations in the PH domain have been shown to result in abnormal cellular processes. Therefore, targeting PLEKHA4 with drugs that modulate its cellular functions could potentially lead to therapeutic benefits for various diseases.

Conclusion:

PLEKHA4 is a unique protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and function, including its ability to interact with various molecules and its role in the MAPK/ERK and cytoskeletal

Protein Name: Pleckstrin Homology Domain Containing A4

Functions: Binds specifically to phosphatidylinositol 3-phosphate (PtdIns3P), but not to other phosphoinositides

The "PLEKHA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLEKHA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets